ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW
Estrella Immunopharma, Inc.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.38−0.05 (-11.65%)
Close on Oct 19, 2026
- Market cap
- $16.17M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.3701 (−78.29%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $16.17M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$7.31M
- EPS, diluted
- -$0.27
- Book value per share
- -$0.17
- Diluted shares
- 43M
Three years at a glance
Fiscal years 2020 to 2024, USD
Operating income
-$7.31M
Net income
-$7.31M
EPS, diluted
-$0.27
Reported period